Search clinical trials for: CUDC-907

Total 1496 results

Dana-Farber Cancer Institute
Curis, Inc.

Active, not recruiting

Trial of CUDC-907 in Children and Young Adults With Relapsed or Refractory Solid Tumors, CNS Tumors, or Lymphoma

Lymphoma | Solid Tumor | Brain Tumor | Neuroblastoma

United States
Curis, Inc.

Completed

Open Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-907 in Subjects With Advanced/Relapsed Solid Tumors

High-grade Serous Ovarian Cancer | Solid Tumors | Triple-Negative Breast Cancer | NUT Midline Carcinoma

United States
National Cancer Institute (NCI)

Terminated

CUDC-907 Treatment in People With Metastatic and Locally Advanced Thyroid Cancer

Thyroid Neoplasms | Differentiated Thyroid Cancer | Poorly Differentiated and Undifferentiated Thyroid Cancer

United States
Curis, Inc.

Completed

Study to Evaluate the Efficacy and Safety of CUDC-907 in Patients With RR DLBCL, Including Patients With MYC Alterations

Relapsed and/or Refractory Diffuse Large B-cell Lymphoma Including With Myc Alterations

United States, Spain
Sabine Mueller, MD, PhD
Pacific Pediatric Neuro-Oncology Consortium; Curis, Inc.; Cannonball Kids' Cancer...

Active, not recruiting

Fimepinostat in Treating Brain Tumors in Children and Young Adults (PNOC016)

Recurrent Glioblastoma | Recurrent Malignant Glioma | Recurrent Medulloblastoma | Diffuse Intrinsic Pontine Glioma | Recurrent Anaplastic Astrocytoma

United States, Switzerland
BeBetter Med Inc

Active, not recruiting

Study of BEBT-908 in the Relapsed or Refractory Diffuse Large B-cell Lymphoma Subjects

Relapsed or Refractory Diffuse Large B-cell Lymphoma

China
BeBetter Med Inc

Completed

Study of BEBT-908 in Subjects With Advanced Hematological Tumors

Relapsed or Refractory Multiple Myeloma | Relapsed or Refractory Non-Hodgkin's Lymphoma

China
Curis, Inc.
The Leukemia and Lymphoma Society

Completed

Study to Assess the Safety, Tolerability and Pharmacokinetics of Fimepinostat (CUDC-907) in Patients With Lymphoma

Lymphoma | Refractory Lymphoma | Relapsed Lymphoma | Relapsed and/or Refractory Lymphoma | Relapsed Ddiffuse Large B-Cell Lymphoma (DLBCL) | Refractory Diffuse Large B-Cell Lymphoma (DLBCL) | Relapsed and/or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) | Double-hit Lymphoma (DHL) | Triple-hit Lymphoma... and other conditions

United States
Curis, Inc.

Completed

A Phase I Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of CUDC-101 in Patients With Advanced Solid Tumors

Tumors

United States
Aarhus University Hospital

Unknown

The Safety and Efficacy of a Novel HSP90 Inhibitor (CUDC-305) in the Treatment of Moderate to Severe Psoriasis.

Psoriasis Vulgaris

Denmark
Curis, Inc.

Terminated

Phase I Study to Assess the Safety, Tolerability, and Pharmacokinetics of Orally Administered CUDC-101 in Cancer Patients

Cancer

United States
Curis, Inc.

Terminated

Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-427 When Given to Patients With Advanced and Refractory Solid Tumors or Lymphoma

Lymphoma

United States
Brian Lally

Completed

Cytochlor, Tetrahydrouridine, and External-Beam Radiation Therapy in Treating Patients With Cancer That Has Spread to the Brain

Brain and Central Nervous System Tumors

United States
Curis, Inc.

Completed

A Phase Ib Expansion Study Investigating the Safety, Efficacy, and Pharmacokinetics of Intravenous CUDC-101 in Subjects With Advanced Head and Neck, Gastric, Breast, Liver and Non-small Cell Lung Cancer Tumors

Breast Cancer | Head and Neck Cancer | Gastric Cancer | Non-Small Cell Lung Cancer | Liver Cancer

United States
Gilead Sciences

Completed

Safety and Efficacy Study of Different Doses of 90Y-hPAM4 Combined With Gemcitabine in Pancreatic Cancer

Pancreatic Cancer

United States
Canopy Growth Corporation
James Madison University

Terminated

CHI-907 CBD Extract and Experiences of Test Anxiety

Anxiety

United States
Duke University

Recruiting

PTSD Mobile App for Cancer Survivors

Cancer | Posttraumatic Stress Disorder

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

2018-0674 - IL-7 for T-Cell Recovery Post Haplo and CB Transplant - Phase I/II

Acute Myeloid Leukemia | Myelodysplastic Syndrome | Myeloproliferative Neoplasm | Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Cord Blood Transplant Recipient

United States
Dayton Children's Hospital
National Institutes of Health (NIH)

Terminated

The Use of VSL#3 in Irritable Bowel Syndrome in Children (VSL#3)

Irritable Bowel Syndrome

United States
Ludwig Institute for Cancer Research
Memorial Sloan Kettering Cancer Center

Completed

Treatment of Patients With Advanced Renal Cancer With a Radiolabeled Antibody, Yttrium-90 Conjugated Chimeric G250

Kidney Cancer | Renal Cell Carcinoma | Renal Cancer | Kidney Neoplasm

United States
Curis, Inc.

Completed

Phase I Study of CUDC-101 With Cisplatin and Radiation in Subjects With Head & Neck Cancer

Head and Neck Cancer

United States
Pfizer

Completed

Long-Term Open-Label Extension Trial for Subjects Completing the Phase 3 Trial of Fesoterodine (SP584) for the Treatment of Overactive Bladder Syndrome

Overactive Bladder Syndrome

United States
Pfizer

Completed

Trial to Investigate the Efficacy, Tolerability and Safety of Fesoterodine Sustained Release in Subjects With Overactive Bladder Syndrome

Overactive Bladder
Pfizer

Completed

Long-Term Open-Label Extension Trial for Subjects Completing the Phase 3 Trial of Fesoterodine (SP583) for the Treatment of Overactive Bladder Syndrome

Overactive Bladder Syndrome

Germany
Pfizer

Completed

A Multicenter Trial to Investigate Fesoterodine Sustained Release in Overactive Bladder Syndrome

Overactive Bladder Syndrome

Germany
H. Lee Moffitt Cancer Center and Research Institute
BTG International Inc.

Completed

Study Of Intrahepatic Arterial Injection of 90-Y Glass Microspheres for Cholangiocarcinoma

Cholangiocarcinoma

United States
Pfizer

Completed

Two Phase Extension Trial of SP668 to Investigate the Safety and Tolerability of Sustained Release Fesoterodine in Subjects With Overactive Bladder: a Double-Blind Phase Followed by an Open-Label Extension Phase

Overactive Bladder

United States
Academisch Medisch Centrum - Universiteit van Amsterdam...

Unknown

Contrast Ultrasound Dispersion Imaging (CUDI) as a Diagnostic Modality in the Diagnosis of Renal Cell Carcinoma (CUDI-RCC)

Kidney Cancer

Netherlands
Sandeep Laroia
National Cancer Institute (NCI); National Institutes of Health (NIH); Holden...

Terminated

Selective Intra-arterial Injection of PRRT in Neuroendocrine Tumor Patients With Liver Metastases

Neuroendocrine Tumors

United States
Fox Chase Cancer Center
Knowledge Networks

Completed

Trial of Print Messages to Support the Role of Partners in Promoting Provider Discussions About Prostate Cancer Screening Among AA Men

Prostate Cancer

United States
Okayama University
Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan

Completed

Transcoronary Infusion of Cardiac Progenitor Cells in Pediatric Dilated Cardiomyopathy (TICAP-DCM)

Dilated Cardiomyopathy

Japan
Johns Hopkins University

Completed

Clinical Practice Guidelines Versus Decision-support for Latent Tuberculosis Infection (LTBI) Management

Latent Tuberculosis

United States
Apollo Therapeutics Ltd

Terminated

A Study to Evaluate Camoteskimab in Participants With Still's Disease

Adult Onset Still's Disease

United States, Belgium, Poland, Ukraine
Nexpep Pty Ltd

Completed

Safety Study of Nexvax2 in Subjects With Coeliac Disease

Celiac Disease | Coeliac Disease

Australia
Dr. August Wolff GmbH & Co. KG Arzneimittel
Parexel

Completed

Safety, Tolerability, Pharmacokinetics and Efficacy of WOL071-007 in Atopic Dermatitis Patients

Dermatitis, Atopic

Germany
Neuromed IRCCS

Withdrawn

Differential Leucocyte Count and Covid-19 Diagnosis

SARS-CoV-2 Infection Covid19

Italy
Hilary L Surratt, PhD
National Institute on Drug Abuse (NIDA)

Active, not recruiting

Integrated PrEP Interventions for People Who Inject Drugs in Rural Kentucky

HIV Prevention

United States
Ciusss de L'Est de l'Île de Montréal

Active, not recruiting

Avatar Intervention for the Treatment of Cannabis Use Disorder in Patients With Severe Mental Health Disorders (Avatar-CUD)

Psychotic Disorders | Mental Health Disorder | Cannabis Use Disorder

Canada
University of California, San Francisco
Taiho Pharmaceutical Co., Ltd.; Sirtex Medical

Completed

Tas-102 and Radioembolization With 90Y Resin Microspheres for Chemo-refractory Colorectal Liver Metastases

Rectal Cancer | Colon Cancer | Liver Metastases

United States
Takeda

Completed

Phase 1 TAK-906 Single and Multiple Ascending Dose Study in Japanese Healthy Male Participants

Japanese Healthy Adult Male Participants

Japan
Rhode Island Hospital
amfAR, The Foundation for AIDS Research

Completed

CDC HIV Testing Guidelines: Unresolved Ethical Concerns

HIV Infections

United States
Alkermes, Inc.

Completed

A Long-term Safety Study of ALKS 9072 (Also Known as ALKS 9070)

Schizophrenia

United States, Bulgaria, Korea, Republic of, Malaysia, Philippines, Romania, Russian Federation, Ukraine
AbbVie

Terminated

A Study to Assess Pharmacokinetics, Safety, and Tolerability of ABBV-903 in Healthy Japanese and Han Chinese Participants

Healthy Volunteers

United States
University of Southern California
National Cancer Institute (NCI)

Withdrawn

Contrast-Enhanced Ultrasound in Diagnosing Patients With Liver Cancer Undergoing Yttrium-90 Radioembolization

Hepatocellular Carcinoma

United States
Qilu Pharmaceutical Co., Ltd.

Unknown

A Study to Investigate the Safety, Efficacy and Pharmacokinetic Profile of Multiple Doses of QL-007 in Chronic Hepatitis B Patients

Chronic Hepatitis b

New Zealand
Alkermes, Inc.

Completed

A Study of ALKS 9072 in Subjects With Chronic Stable Schizophrenia

Schizophrenia

United States
Nanjing Leads Biolabs Co.,Ltd

Recruiting

Phase Ib/II Clinical Study of LBL-007 in Treatment of Advanced Malignant Tumors

Advanced Solid Tumor

China
Suzhou Yabao Pharmaceutical R&D Co., Ltd.

Suspended

SY007 in Patients With Acute Ischemic Stroke

Acute Ischemic Stroke

China
Pentixapharm AG

Recruiting

[90Y]Y-PTT Endoradiotherapy in CNS Lymphoma Patients

CNS Lymphoma

Germany
Recognify Life Sciences

Completed

Safety, Biomarker Study of RL-007 in Subjects With Schizophrenia

Schizophrenia | Cognitive Impairment

United States

Search clinical trials for: CUDC-907

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Lithuania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations